Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-527 Safety and PK Study in Healthy Adults
NCT05256732Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bemnifosbuvir in coronavirus disease 2019 (COVID-19) and hepatitis C (HCV) (5 arms), sponsored by Atea Pharmaceuticals. Primary endpoints: Pharmacokinetics of AT-527 at Day 1 and Proportions of subjects experiencing treatment-emergent adverse events. Started Feb 2022; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05256732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05256732.